Now livetag icon
What will define the 2026 holiday season? 🔎 See how shoppers are deciding. Download the report →banner icon
Remegen

March 2026

Remegen Market Share Analysis for March 2026

Industry: N/A
Year Founded2008
Employees1001 - 5000
Annual Revenue--
remegen.com
Remegen
Remegen (including company regionals)
  • remegen.com
    remegen.com
See more website traffic and engagement information

Total visits to Remegen's top domains

Understand Remegen market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

Avg. visit duration in Remegen's top domains

Analyze Remegen engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

Avg. pageviews on Remegen's top domains

See how Remegen keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.


Remegen top competitors by domain

Looks like there’s not enough data here

No Data to Display

Benchmark Your Digital Performance

Identify high-value opportunities, track your performance, and win your market.


Top technologies used by Remegen

These are the website technologies, by industry, used by Remegen top domains

Mobile (3)

Meta Viewport

Meta Viewport

Social (3)

Facebook Social Plugins

Facebook Social Plugins

Advertising (2)

PubMatic

PubMatic

Conversion & Analytics (2)

Google Analytics

Google Analytics

More Technologies

5

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from Remegen

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsRemeGen, Ltd. is developing novel PD-1/VEGF bispecific on Jan 12th '26.* Jan 12: AbbVie and RemeGen Biosciences announce licensing agreement to develop a novel PD-1/VEGF bispecific in potential $5.6B deal.
NewsRemeGen, Ltd. is developing Programmed Cell Death-1.AbbVie is partnering with Chinese biotech RemeGen to develop a novel Programmed Cell Death-1 (PD-1)/Vascular Endothelial Growth Factor (VEGF)-targeted bispecific antibody (bsAb), in a deal potentially worth up to $4.95 billion.
NewsAbbVie partners with RemeGen, Ltd..AbbVie secures a licensing agreement with RemeGen for RC148, a bispecific antibody for advanced solid tumors.

See all Remegen signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.